Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryDiabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trialsCardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-AnalysesDiabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future researchErectile dysfunction in heart failure patients: a critical reappraisalThe 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - TherapyALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analysesClinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Understanding the quality chasm for hypertension control in diabetes: a structured review of "co-maneuvers" used in clinical trials.Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBThiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension.Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.2010 Canadian Hypertension Education Program recommendations: An annual update.Pathophysiologic therapeutic targets in hypertension: a cardiological point of view.Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial.Achieved blood pressures in the secondary prevention of small subcortical strokes (SPS3) study: challenges and lessons learned.Diabetes & coronary heart disease: current perspectives.Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study.Hypertension in people with type 2 diabetes: Update on pharmacologic management.Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) studyEmerging drug combinations to optimize renovascular protection and blood pressure goals.Rebuttal: Do beta-blockers have a role in treating hypertension? NoPharmacotherapy review: angiotensin-converting enzyme inhibitors.Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT])Antihypertensive medications and blood sugar: theories and implications.Diagnosis and management of stage a heart failure.Diuretics: a modern day treatment option?Treating the metabolic syndrome.First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.Why is blood pressure so hard to control in patients with type 2 diabetes?Highlights and summary of the 2006 Canadian Hypertension Education Program recommendations.Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelinesDoes renin angiotensin system blockade deserve preferred status over other anti-hypertensive medications for the treatment of people with diabetes?Update on the Canadian Diabetes Association 2008 clinical practice guidelines.Type 2 diabetes mellitus and heart failure.Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan.Type 2 diabetes mellitus: prevention of macrovascular complications.Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.Hypertension in diabetes: a call to action.
P2860
Q22241786-4BFDC5D4-14E4-4355-B68E-FCA640CC449BQ26766599-A0C50AEE-7FC6-49EF-A94D-FA5293BD4B23Q26767278-5759C2F8-B982-4EC0-A046-E73479F12FB1Q26782844-DD1D2EB9-0ACA-49E7-ACC2-F16B844A681AQ26853624-F7098453-B35B-4B4D-AEFD-225A7DF3B130Q28218811-69DFB3DF-3A08-48A1-8528-47F4043C8FAFQ33576830-38A9E5F1-0F57-4409-B5D6-70A58B1D526BQ33584703-9EFF7B3C-3B12-49E0-9C55-8CCDB324662DQ33750286-935B44ED-7D1D-43FB-9225-BAA0F49434A1Q33908782-47C67EC1-B07E-4A9E-9D90-0DC1D7326F89Q33964868-36681109-C79E-4759-BB38-D0C727589D3EQ33964875-97F03775-6AA8-416C-9728-BC068BDC9447Q33965660-44BCC6E1-7A19-45DA-9649-3203627FCE20Q34066861-05A64398-BBB0-4655-8079-47AC56924AE1Q34142036-058FAA35-231C-4AB7-997B-22FFCC1E462BQ34279210-599E8559-4F05-427A-94F7-B8A11F133CB0Q34285841-59D048CF-351F-4AFA-BC26-CF3039AD8E86Q34530098-48EDD299-F666-4855-9182-1FF5F03E2E4AQ34574001-B1818B50-8A50-4838-A0DB-312828EAB77AQ35213902-E89F0D59-88C2-457D-B7D2-24BF788A209FQ35856525-F9330180-F5D1-4F0D-A5B7-D45F963E6F3FQ35905899-EAA6198B-3092-432E-BFA3-EFCD3232B995Q35941885-95A2A3B8-AD50-4527-99CD-3F056385C334Q36231663-9A5C7DD6-697C-4E81-8168-DE35F3DFE87DQ36403208-63283624-10FF-46D3-9917-F98FBBFE3127Q36415349-DAA96FCB-7392-4F16-951D-24AABF7EA1D4Q36499956-1BF3789A-4102-4285-85DD-D8AE4079F6CEQ36609875-17F43947-E2EC-4746-9256-49EEC5FA97DAQ36815978-B42E36A3-B8E3-45D1-9A97-C060B9FD6CE2Q36862389-C7C46DCF-EA57-431E-98D9-77FFB1C37C60Q36904456-4C8748C1-199C-4EE6-A2D6-6F8AF47B8244Q36921849-59C80896-25A0-4B6C-90F6-C42E2AE6954EQ36932658-28C4957D-F0AA-4468-BFFE-25D84B878252Q36948768-AF2B8050-147E-48A1-B7D3-705715ECCD8AQ37067401-D7F1791E-1697-4E8C-B60A-15EDB8448F03Q37069176-6AAA0BAC-E18E-4D2D-8D8E-654776968D3CQ37104853-A4E7BC8C-2113-4306-A857-BC464FD0751EQ37104865-C473443F-C8CC-4931-B06F-64A89F0DB93EQ37202153-5763DF59-40E1-4D18-82E5-F59D442A7ADBQ37253892-FCFF7D78-4070-4AE5-A837-E3C5B8014BBF
P2860
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Clinical outcomes in antihyper ...... t Heart Attack Trial (ALLHAT).
@en
Clinical outcomes in antihyper ...... t Heart Attack Trial (ALLHAT).
@nl
type
label
Clinical outcomes in antihyper ...... t Heart Attack Trial (ALLHAT).
@en
Clinical outcomes in antihyper ...... t Heart Attack Trial (ALLHAT).
@nl
prefLabel
Clinical outcomes in antihyper ...... t Heart Attack Trial (ALLHAT).
@en
Clinical outcomes in antihyper ...... t Heart Attack Trial (ALLHAT).
@nl
P2093
P1476
Clinical outcomes in antihyper ...... nt Heart Attack Trial (ALLHAT)
@en
P2093
ALLHAT Collaborative Research Group
Barry R Davis
Chuke Nwachuku
David C Parish
David E Mathis
Deborah Panebianco
Debra L Simmons
Ekambaram Iiamathi
Frans H H Leenen
Gail T Louis
P304
P356
10.1001/ARCHINTE.165.12.1401
P407
P577
2005-06-01T00:00:00Z